Stifel downgraded Baxter to 'Hold' after a soft Q2 and trimmed 2025 outlook. EPS missed estimates, and guidance was narrowed amid weak IV fluid demand and drug sales. Tariff impact forecast improved, and new CEO Andrew Hider joins in September. Despite 25% YTD fall, retail sentiment on Stocktwits is 'extremely bullish'.